�����ƽ��

Overview of the derivation of human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs)

Technical tip from our dedicated team of Product and Scientific Support specialists

Each year, more human pluripotent stem cell-derived (hPSC-derived) therapies move towards the clinic, and �����ƽ�� is committed to supporting researchers from discovery to clinical application. In this Innovation Showcase from ISSCR 2021, Lynn Csontos will demonstrate how we build quality into our products, processes, and policies to support your project timing, product quality, and overall vision. Kimberly Snyder will then present data that shows how TeSR™-AOF, a novel animal origin-free (AOF) hPSC maintenance medium, can support optimized cell quality, improved performance and reproducibility across all cell lines.

Technical tip from our dedicated team of Product and Scientific Support specialists

In this talk, Andrew Gaffney is joined by Stephen Sullivan from the Global Alliance for iPSC Therapies (GAiT) to discuss the importance of iPSC characterization as well as risks and mitigation strategies involved in creating a cell therapy.

This webinar describes steps and considerations involved in translating research to the clinic.

In this talk, Drs. Sandra Petrus-Reurer and Álvaro Plaza Reyes share their research on using human pluripotent stem cell (hPSC)-derived retinal epithelial cells (RPE) to treat age-related macular degeneration (AMD) and describe the steps and hurdles associated with bringing an hPSC-derived product to the clinic. This seminar is followed by a presentation from Lynn Csontos, in-house quality expert from �����ƽ�� Technologies, who discusses compliance considerations for clinical-grade induced pluripotent stem cells.

Dr. Peter Coffey from University College London shares his work with the London Project to Cure Blindness, which resulted in the first clinical stem cell trial to treat blindness, and discusses cell quality requirements for clinical trials. This presentation and the following Q&A session were moderated by Dr. Christine Mummery from the Leiden University Medical Center. <br><br> This presentation was part of a Round Table series titled “Challenges in Ensuring hPSC Quality”, hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series <a href="/nature-research-roundtable-hPSC-quality#section-webcasts">here</a>. <br><br> Note: Some original data from this presentation has been omitted to abide by copyright rules.

Dr. Malin Parmar from Lund University talks about her work on cell-based therapies to treat Parkinson’s disease, as well as regulatory, safety, and efficacy requirements for the clinic. This presentation and the following Q&A session were moderated by Dr. Christine Mummery from the Leiden University Medical Center. <br><br> This presentation was part of a Round Table series titled “<a href="/nature-research-roundtable-hPSC-quality#section-webcasts">Challenges in Ensuring hPSC Quality</a>”, hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series <a href="/nature-research-roundtable-hPSC-quality#section-webcasts">here</a>. <br><br> Note: Some original data from this presentation has been omitted to abide by copyright rules.